Pyrexia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:04 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pyrexia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of 18F-AlF-FAPI-74 PET/CT imaging compared to standard 18F-FDG PET/CT in patients with fever of unknown origin, IgG4-related disease, and axial spondyloarthritis https://clinicaltrials.eu/trial/study-on-pet-ct-imaging-for-fever-of-unknown-origin-igg4-related-disease-and-axial-spondyloarthritis-using-18ffapi-74-and-18ffdg/ Wed, 29 Apr 2026 15:04:54 +0000 https://clinicaltrials.eu/trial/study-on-pet-ct-imaging-for-fever-of-unknown-origin-igg4-related-disease-and-axial-spondyloarthritis-using-18ffapi-74-and-18ffdg/ This study focuses on evaluating a new imaging method for several inflammatory conditions including Fever of Unknown Origin, IgG4-related Disease, and Axial Spondyloarthritis. The study compares two different imaging tracers: a new substance called [18F]AlF-FAPI-74 and the standard tracer [18F]FDG, both used in combination with PET/CT scanning. PET/CT is an advanced imaging technique that combines two types of scans to create detailed pictures of the body.

The purpose of this research is to determine if the new imaging tracer can work as well as or better than the current standard method in detecting and evaluating inflammatory conditions. The study will look at how well each tracer can identify the source of unexplained fever and inflammation, assess the extent of IgG4-related disease (a condition that can affect multiple organs), and distinguish between inflammatory and mechanical back pain in patients with spine problems.

During the study, participants will receive an intravenous injection of the imaging tracer before undergoing the PET/CT scan. Some participants may need to have two scans, particularly those with spine conditions who will be evaluated before and after three months of treatment. The maximum amount of tracer used for each scan will be 100 MBq, with a total maximum dose of 550 MBq over the entire study period.

]]> Study on the Safety and Immune Response of the 20-Valent Pneumococcal Vaccine in Adults with Fever and High Risk for Pneumococcal Infection https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-the-20-valent-pneumococcal-vaccine-in-adults-with-fever-and-high-risk-for-pneumococcal-infection/ Wed, 29 Apr 2026 15:03:48 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-the-20-valent-pneumococcal-vaccine-in-adults-with-fever-and-high-risk-for-pneumococcal-infection/ This clinical trial is focused on studying the effects of the 20-Valent pneumococcal conjugate vaccine (PCV-20) in adults who are at medium or high risk for pneumococcal infections. Pneumococcal infections are caused by bacteria that can lead to serious illnesses like pneumonia, meningitis, and bloodstream infections. The vaccine being tested, known as Prevenar 20, is designed to protect against 20 different types of these bacteria. The study aims to compare the immune response of patients who receive the vaccine during an acute febrile illness, which is a sudden fever, to those who receive it after their fever has resolved.

Participants in the study will be randomly assigned to one of two groups. One group will receive the vaccine while they are experiencing a fever, and the other group will receive it 15 to 58 days after their fever has subsided. The study will monitor the immune response of participants one month after vaccination to determine if the timing of the vaccine affects its effectiveness. The study will also track the safety of the vaccine by recording any side effects or reactions that occur within a month after vaccination.

In addition to the primary focus on immune response and safety, the study will also look at other factors over a year, such as the number of respiratory infections and confirmed Streptococcus pneumoniae infections in participants. The study will explore the diversity of gut bacteria and the presence of specific immune cells and antibodies related to the vaccine. This research will help determine the best timing for administering the PCV-20 vaccine to adults at risk for pneumococcal infections.

]]>